Bellevue Group AG
Institutional InvestorSimilar funds →SEC EDGAR: CIK 1674546
Institutional-grade research for retail investors
Email me the moment this fund files its next 13F
13F Reported Value
ⓘ$4.8B
Holdings
148
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Bellevue Group AG disclosed 148 positions worth $4.8B in its Form 13F-HR for Q2 2026, led by $AMGN (AMGEN INC) at 6.5% of the equity portfolio, followed by $VRTX and $ARGX. During the quarter the fund opened 17 new positions and exited 24 — including a new stake in $AVLN and a full exit from $EWTX. The portfolio is most concentrated in Healthcare (97.5% of disclosed assets). All figures are sourced directly from Bellevue Group AG’s Form 13F-HR filing with the SEC under CIK 1674546.
AI Fund Analysis
Stable
$AMGN6.5% weight
Held 10 quarters
$VRTX6.0% weight
Held 10 quarters
$ARGX5.9% weight
Held 10 quarters
$GILD5.7% weight
Held 10 quarters
$RVMD4.1% weight
Held 10 quarters
$BBIO4 quarters accumulating
$MDGL4 quarters accumulating
$AMGN3 quarters accumulating
$GILD3 quarters accumulating
$VRDN3 quarters accumulating
Sector Allocation
HealthcareTechnologyConsumer StaplesConsumer DiscretionaryOtherIndustrials
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
AI Quality Scored
- 79.2#43
Quality
$308.4M851,550 sh - 75.4#98
Quality
$287.4M578,634 sh - —
Quality
$279.3M301,000 sh - 57.4
Quality
$272.7M2,158,772 sh - —
Quality
$196.3M1,048,014 sh - —
Quality
$157.7M1,657,190 sh - 39.4
Quality
$148.6M1,393,418 sh - —
Quality
$134.7M2,449,547 sh - —
Quality
$130.1M1,053,268 sh - 27.2
Quality
$123.7M6,731,909 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| AMGEN INC$AMGN | 79.2#43 | $308.4M | 851,550 |
| VERTEX PHARMACEUTICALS INC / MA$VRTX | 75.4#98 | $287.4M | 578,634 |
| ARGENX SE$ARGX | — | $279.3M | 301,000 |
| GILEAD SCIENCES, INC.$GILD | 57.4 | $272.7M | 2,158,772 |
| Revolution Medicines, Inc.$RVMD | — | $196.3M | 1,048,014 |
 Oruka Therapeutics, Inc.$ORKA | — | $157.7M | 1,657,190 |
 INSMED Inc$INSM | 39.4 | $148.6M | 1,393,418 |
 Scholar Rock Holding Corp$SRRK | — | $134.7M | 2,449,547 |
 Nuvalent, Inc.$NUVL | — | $130.1M | 1,053,268 |
| Viridian Therapeutics, Inc.\DE$VRDN | 27.2 | $123.7M | 6,731,909 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Bellevue Group AG's 148 positions.
Showing top 10 of 148 holdings.
Sector Allocation
Healthcare
$4.6B
Technology
$101.3M
Consumer Staples
$7.6M
Consumer Discretionary
$5.5M
Other
$2.5M
Industrials
$1.4M
Full Holdings — Bellevue Group AG (Q2 2026)
All 148 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AMGN | AMGEN INC | $308.4M | 6.5% | +188% | 79.2 |
| 2 | $VRTX | VERTEX PHARMACEUTICALS INC / MA | $287.4M | 6.0% | -15% | 75.4 |
| 3 | $ARGX | ARGENX SE | $279.3M | 5.9% | -4% | — |
| 4 | $GILD | GILEAD SCIENCES, INC. | $272.7M | 5.7% | +85% | 57.4 |
| 5 | $RVMD | Revolution Medicines, Inc. | $196.3M | 4.1% | -32% | — |
| 6 | $ORKA | Oruka Therapeutics, Inc. | $157.7M | 3.3% | +227% | — |
| 7 | $INSM | INSMED Inc | $148.6M | 3.1% | NEW | 39.4 |
| 8 | $SRRK | Scholar Rock Holding Corp | $134.7M | 2.8% | -32% | — |
| 9 | $NUVL | Nuvalent, Inc. | $130.1M | 2.7% | +0% | — |
| 10 | $VRDN | Viridian Therapeutics, Inc.\DE | $123.7M | 2.6% | +0% | 27.2 |
| 11 |  $RLAY | Relay Therapeutics, Inc. | $115.7M | 2.4% | -21% | 19.5 |
| 12 |  $PCVX | Vaxcyte, Inc. | $114.6M | 2.4% | +66% | — |
| 13 |  $UTHR | UNITED THERAPEUTICS Corp | $102.1M | 2.1% | +8976% | 71.3 |
| 14 |  $ISRG | INTUITIVE SURGICAL INC | $101.3M | 2.1% | -11% | 79.9 |
| 15 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $98.1M | 2.1% | -44% | 71 |
| 16 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $98.0M | 2.1% | -20% | 25.5 |
| 17 | $BBIO | BridgeBio Pharma, Inc. | $88.6M | 1.9% | +4587% | 36.9 |
| 18 |  $IMCR | Immunocore Holdings plc | $88.5M | 1.9% | -0% | — |
| 19 |  $ABT | ABBOTT LABORATORIES | $85.9M | 1.8% | -18% | 65.5 |
| 20 |  $SYK | STRYKER CORP | $84.5M | 1.8% | +24% | 72.1 |
| 21 |  $MDT | Medtronic plc | $77.8M | 1.6% | +4% | 68.7 |
| 22 |  $IONS | IONIS PHARMACEUTICALS INC | $77.1M | 1.6% | -47% | 23.4 |
| 23 |  $ELVN | Enliven Therapeutics, Inc. | $75.6M | 1.6% | -36% | — |
| 24 |  $VERA | Vera Therapeutics, Inc. | $73.4M | 1.5% | +0% | — |
| 25 |  $JBIO | Jade Biosciences, Inc. | $67.9M | 1.4% | -13% | — |
| 26 |  $EW | Edwards Lifesciences Corp | $66.9M | 1.4% | -12% | 69.4 |
| 27 |  $RARE | Ultragenyx Pharmaceutical Inc. | $66.2M | 1.4% | -17% | 34.2 |
| 28 |  $UNH | UNITEDHEALTH GROUP INC | $62.0M | 1.3% | +1% | 62.7 |
| 29 |  $DXCM | DEXCOM INC | $55.4M | 1.2% | +4% | 76 |
| 30 |  $CLDX | Celldex Therapeutics, Inc. | $44.7M | 0.9% | +0% | 8.4 |
| 31 |  $AVLN | Avalyn Pharma Inc. | $44.4M | 0.9% | NEW | — |
| 32 |  $DMRA | Damora Therapeutics, Inc. | $42.1M | 0.9% | -30% | — |
| 33 |  $IRON | Disc Medicine, Inc. | $41.0M | 0.9% | +22% | — |
| 34 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $40.0M | 0.8% | +24% | 65.1 |
| 35 |  $BSX | BOSTON SCIENTIFIC CORP | $37.9M | 0.8% | -39% | 77.5 |
| 36 |  $LLY | ELI LILLY & Co | $35.8M | 0.8% | -12% | 87.5 |
| 37 |  $CGON | CG Oncology, Inc. | $35.1M | 0.7% | NEW | 27 |
| 38 |  $IDXX | IDEXX LABORATORIES INC /DE | $32.5M | 0.7% | -31% | 73.8 |
| 39 |  $RMD | RESMED INC | $28.9M | 0.6% | -7% | 74.3 |
| 40 |  $KRYS | Krystal Biotech, Inc. | $28.8M | 0.6% | -84% | 79.2 |
| 41 |  $GLUE | Monte Rosa Therapeutics, Inc. | $28.8M | 0.6% | -5% | 30.3 |
| 42 |  $DHR | DANAHER CORP /DE/ | $27.4M | 0.6% | -29% | 64.8 |
| 43 |  $JNJ | JOHNSON & JOHNSON | $26.2M | 0.6% | -13% | 69 |
| 44 |  $SPTX | Seaport Therapeutics, Inc. | $23.9M | 0.5% | NEW | — |
| 45 |  $PVLA | PALVELLA THERAPEUTICS, INC. | $23.7M | 0.5% | NEW | — |
| 46 |  $ALGN | ALIGN TECHNOLOGY INC | $23.6M | 0.5% | +0% | 58.9 |
| 47 |  $ANNX | Annexon, Inc. | $23.4M | 0.5% | -21% | — |
| 48 |  $HUM | HUMANA INC | $23.2M | 0.5% | -9% | 58.9 |
| 49 |  $ELV | Elevance Health, Inc. | $21.8M | 0.5% | +7% | 59 |
| 50 |  $TNGX | Tango Therapeutics, Inc. | $21.7M | 0.5% | -71% | 17.6 |
| 51 |  $STE | STERIS plc | $21.0M | 0.4% | -0% | — |
| 52 |  $SYRE | Spyre Therapeutics, Inc. | $20.4M | 0.4% | NEW | — |
| 53 |  $COAG | Hemab Therapeutics Holdings, Inc. | $20.2M | 0.4% | NEW | — |
| 54 |  $PODD | INSULET CORP | $19.4M | 0.4% | -22% | 71.3 |
| 55 |  $CI | Cigna Group | $18.3M | 0.4% | -32% | 66.2 |
| 56 |  $GKOS | GLAUKOS Corp | $18.0M | 0.4% | -12% | 40.5 |
| 57 |  $CVS | CVS HEALTH Corp | $17.5M | 0.4% | +90% | 59.4 |
| 58 |  $BDX | BECTON DICKINSON & CO | $16.6M | 0.3% | -10% | 59 |
| 59 |  $GEHC | GE HealthCare Technologies Inc. | $16.2M | 0.3% | -39% | 55.7 |
| 60 |  $LIVN | LivaNova PLC | $16.1M | 0.3% | +5% | — |
| 61 |  $CNC | CENTENE CORP | $14.7M | 0.3% | -12% | 58.2 |
| 62 |  $MRK | Merck & Co., Inc. | $14.5M | 0.3% | -45% | 59.9 |
| 63 |  $COO | COOPER COMPANIES, INC. | $14.1M | 0.3% | -28% | 57 |
| 64 |  $PBLS | Parabilis Medicines, Inc. | $13.7M | 0.3% | NEW | — |
| 65 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $11.7M | 0.3% | +38% | — |
| 66 |  $GMED | GLOBUS MEDICAL INC | $11.5M | 0.2% | -41% | 79.5 |
| 67 |  $PRCT | PROCEPT BioRobotics Corp | $11.3M | 0.2% | +0% | 33.3 |
| 68 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $10.9M | 0.2% | -19% | 65.7 |
| 69 |  $VEEV | VEEVA SYSTEMS INC | $10.5M | 0.2% | +5% | 77.6 |
| 70 |  $ABBV | AbbVie Inc. | $10.2M | 0.2% | -57% | 72.6 |
| 71 |  $TXG | 10x Genomics, Inc. | $10.0M | 0.2% | -21% | 40.5 |
| 72 |  $HCA | HCA Healthcare, Inc. | $9.3M | 0.2% | -37% | 68.9 |
| 73 |  $AURA | Aura Biosciences, Inc. | $8.3M | 0.2% | NEW | — |
| 74 |  $MCK | MCKESSON CORP | $7.3M | 0.1% | -57% | 63.4 |
| 75 |  $THC | TENET HEALTHCARE CORP | $7.3M | 0.1% | +2% | 66.2 |
| 76 |  $PTGX | Protagonist Therapeutics, Inc | $6.8M | 0.1% | +285% | 59.4 |
| 77 |  $NTRA | Natera, Inc. | $6.7M | 0.1% | -22% | 53.5 |
| 78 |  $TMDX | TransMedics Group, Inc. | $6.7M | 0.1% | +0% | 67.2 |
| 79 |  $MOH | MOLINA HEALTHCARE, INC. | $6.3M | 0.1% | NEW | 56.5 |
| 80 |  $ALKS | Alkermes plc. | $6.3M | 0.1% | +1256% | — |
| 81 |  $RPRX | Royalty Pharma plc | $6.3M | 0.1% | +193% | — |
| 82 |  $WAY | Waystar Holding Corp. | $6.0M | 0.1% | +15% | 65.5 |
| 83 |  $PRVA | Privia Health Group, Inc. | $5.8M | 0.1% | +0% | 60.1 |
| 84 |  $GMRS | GMR Solutions Inc. | $5.2M | 0.1% | NEW | — |
| 85 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $4.1M | 0.1% | +417% | 76.5 |
| 86 |  $OMDA | Omada Health, Inc. | $3.5M | 0.1% | +0% | 59.4 |
| 87 |  $KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | $3.3M | 0.1% | +12% | — |
| 88 |  $MDLN | Medline Inc. | $3.2M | 0.1% | -40% | 62.5 |
| 89 |  $ILMN | ILLUMINA, INC. | $3.2M | 0.1% | -10% | 60.4 |
| 90 |  $ONC | BeOne Medicines Ltd. | $3.0M | 0.1% | +175% | — |
| 91 |  $NAMS | NewAmsterdam Pharma Co N.V. | $2.9M | 0.1% | +215% | — |
| 92 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $2.5M | 0.1% | +54% | 40.7 |
| 93 |  $SPY | SPDR S&P 500 ETF TRUST | $2.0M | 0.0% | +0% | — |
| 94 |  $BNTX | BioNTech SE | $2.0M | 0.0% | +2% | — |
| 95 |  $ADPT | Adaptive Biotechnologies Corp | $1.9M | 0.0% | +17% | 41.4 |
| 96 |  $CYTK | CYTOKINETICS INC | $1.6M | 0.0% | +115% | 28.1 |
| 97 |  $ALMR | Alamar Biosciences, Inc. | $1.5M | 0.0% | NEW | — |
| 98 |  $PHR | Phreesia, Inc. | $1.4M | 0.0% | +7% | 57.3 |
| 99 |  $MOBI | Mobia Medical, Inc. | $1.3M | 0.0% | NEW | — |
| 100 |  $BLLN | BillionToOne, Inc. | $1.3M | 0.0% | +0% | 61.9 |
| 101 |  $BBNX | Beta Bionics, Inc. | $1.1M | 0.0% | +0% | 29.8 |
| 102 |  $LEGN | Legend Biotech Corp | $954,600 | 0.0% | -8% | 47.8 |
| 103 |  $PFE | PFIZER INC | $925,418 | 0.0% | -64% | 62 |
| 104 |  $ABVX | Abivax S.A. | $852,464 | 0.0% | +510% | — |
| 105 |  $EHC | Encompass Health Corp | $702,607 | 0.0% | -29% | 66.9 |
| 106 |  $AXSM | Axsome Therapeutics, Inc. | $658,187 | 0.0% | -15% | 40.8 |
| 107 |  $CERT | Certara, Inc. | $651,345 | 0.0% | +0% | 39.1 |
| 108 |  $AGMB | Agomab Therapeutics NV | $639,239 | 0.0% | -2% | — |
| 109 |  $PRAX | Praxis Precision Medicines, Inc. | $618,357 | 0.0% | +5% | — |
| 110 |  $AAPL | Apple Inc. | $540,524 | 0.0% | -47% | 76.4 |
| 111 |  $GRMN | GARMIN LTD | $469,379 | 0.0% | +50% | — |
| 112 |  $DNLI | Denali Therapeutics Inc. | $456,942 | 0.0% | +0% | — |
| 113 | — | VANECK ETF TRUST - GOLD MINERS ETF | $433,838 | 0.0% | +0% | — |
| 114 |  $MANE | Veradermics, Inc | $426,356 | 0.0% | NEW | — |
| 115 |  $GOOG | Alphabet Inc. | $395,609 | 0.0% | +189% | 78.2 |
| 116 |  $DFTX | Definium Therapeutics, Inc. | $394,713 | 0.0% | NEW | — |
| 117 |  $TVTX | Travere Therapeutics, Inc. | $392,443 | 0.0% | -22% | 56.6 |
| 118 |  $AMZN | AMAZON COM INC | $382,536 | 0.0% | +19% | 68.7 |
| 119 |  $HALO | HALOZYME THERAPEUTICS, INC. | $340,318 | 0.0% | +13% | 77.2 |
| 120 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $328,725 | 0.0% | -100% | 71.4 |
| 121 |  $CRSP | CRISPR Therapeutics AG | $317,314 | 0.0% | +16% | 9.7 |
| 122 |  $GPCR | Structure Therapeutics Inc. | $255,577 | 0.0% | -30% | — |
| 123 |  $VTRS | Viatris Inc | $250,555 | 0.0% | NEW | 45.4 |
| 124 |  $MLYS | Mineralys Therapeutics, Inc. | $236,156 | 0.0% | -70% | — |
| 125 |  $SMMT | Summit Therapeutics Inc. | $222,615 | 0.0% | -4% | — |
| 126 |  $CAH | CARDINAL HEALTH INC | $202,401 | 0.0% | -1% | 62.4 |
| 127 |  $COGT | Cogent Biosciences, Inc. | $188,469 | 0.0% | NEW | — |
| 128 |  $TEM | Tempus AI, Inc. | $186,129 | 0.0% | -35% | 41.2 |
| 129 |  $COR | Cencora, Inc. | $162,996 | 0.0% | -66% | 61.1 |
| 130 |  $PTCT | PTC THERAPEUTICS, INC. | $132,633 | 0.0% | -16% | 35.4 |
| 131 |  $CAI | Caris Life Sciences, Inc. | $114,369 | 0.0% | +0% | 69 |
| 132 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $112,806 | 0.0% | +0% | 33.9 |
| 133 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $97,078 | 0.0% | -23% | 38.7 |
| 134 |  $NVDA | NVIDIA CORP | $81,637 | 0.0% | +0% | 85.9 |
| 135 |  $LH | LABCORP HOLDINGS INC. | $78,400 | 0.0% | +0% | 65 |
| 136 |  $BIIB | BIOGEN INC. | $73,028 | 0.0% | -91% | 64.7 |
| 137 |  $BMY | BRISTOL MYERS SQUIBB CO | $70,066 | 0.0% | -93% | 70.4 |
| 138 |  $WAT | WATERS CORP /DE/ | $67,132 | 0.0% | NEW | 60.4 |
| 139 |  $MSFT | MICROSOFT CORP | $64,159 | 0.0% | +0% | 79.8 |
| 140 |  $IQV | IQVIA HOLDINGS INC. | $56,613 | 0.0% | -60% | 61.4 |
| 141 |  $INCY | INCYTE CORP | $55,093 | 0.0% | +0% | 77.4 |
| 142 |  $MTD | METTLER TOLEDO INTERNATIONAL INC/ | $45,990 | 0.0% | +0% | 67.5 |
| 143 |  $A | AGILENT TECHNOLOGIES, INC. | $43,834 | 0.0% | -50% | 67.1 |
| 144 |  $QCOM | QUALCOMM INC/DE | $36,404 | 0.0% | +0% | 70.5 |
| 145 |  $ZTS | Zoetis Inc. | $28,025 | 0.0% | -27% | 68.6 |
| 146 |  $ORCL | ORACLE CORP | $27,991 | 0.0% | +0% | 66.2 |
| 147 |  $DGX | QUEST DIAGNOSTICS INC | $27,765 | 0.0% | +0% | 69 |
| 148 |  $RXRX | RECURSION PHARMACEUTICALS, INC. | $16,981 | 0.0% | +0% | 23.3 |
New Positions (17)
$AVLN Avalyn Pharma Inc.$44.4M$CGON CG Oncology, Inc.$35.1M$SPTX Seaport Therapeutics, Inc.$23.9M$PVLA PALVELLA THERAPEUTICS, INC.$23.7M$SYRE Spyre Therapeutics, Inc.$20.4M$COAG Hemab Therapeutics Holdings, Inc.$20.2M$PBLS Parabilis Medicines, Inc.$13.7M$AURA Aura Biosciences, Inc.$8.3M$MOH MOLINA HEALTHCARE, INC.$6.3M$GMRS GMR Solutions Inc.$5.2M$ALMR Alamar Biosciences, Inc.$1.5M$MOBI Mobia Medical, Inc.$1.3M$MANE Veradermics, Inc$426,356$DFTX Definium Therapeutics, Inc.$394,713$VTRS Viatris Inc$250,555Exited Positions (24)
$EWTX Edgewise Therapeutics, Inc.
$INSP Inspire Medical Systems, Inc.
$PEN Penumbra Inc
$RNA.R1599901 Avidity Biosciences, Inc.
$MASI MASIMO CORP
$EQNR EQUINOR ASA
$XOM.R34088 EXXON MOBIL CORP
$BP BP PLC
$SHEL Shell plc
$CSCO CISCO SYSTEMS, INC.
$BABA Alibaba Group Holding Ltd
$PG PROCTER & GAMBLE Co
$MA Mastercard Inc
$BLK BlackRock, Inc.
$V VISA INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Bellevue Group AG including:
Full 13F portfolio with all holdings
Quarter-over-quarter position changes
Accumulation & distribution patterns
Sector allocation breakdown
Historical portfolio evolution
New positions & complete exits
Concentration analysis
Peer comparison with similar funds
AI-powered portfolio insights
Track Bellevue Group AG's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Bellevue Group AG and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
Passwordless sign-in · Payments by Stripe · Auth by Clerk
AI-Powered Hedge Fund Analysis: Bellevue Group AG
13F Pro is an AI hedge fund tracker and stock research platform. For Bellevue Group AG (SEC CIK: 1674546), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Bellevue Group AG's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.